In this video Prof. Sven Francque explores that NAFLD is prevalent in patients with cardiovascular disease, but this does not prove bidirectional causality. Vascular mechanisms contribute to NASH pathogenesis and drugs used in CVD management show some benefit on NAFLD.
In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
This slides set presents a detailed review of vascular alterations in non-alcoholic steatohepatitis (NASH) and NASH cirrhosis delivered by Professor Francque, MD, PhD. He highlights that non-fibrotic non-alcoholic fatty liver disease (NAFLD) is accompanied by a significant rise in portal pressure. Professor Francque, also explains the effects of intrahepatic vascular resistance increase in NAFLD. To the clinicians, he provides various patient studies, statistics and clinical data on the subject.
In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.
Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.
2020 started with an important discussion about the terminology to be used regarding Non Alcoholic Fatty Liver Disease (NAFLD). In this exclusive interview for the PanNASH web site, Prof Sven Francque discusses the rationale of this change and the possible impact in clinical practice
In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
In this Expert perspective video, Prof Sven Francque explains how to make the distinction between NAFL and NASH. This is important even though in clinical practice there is a continuum between the two. In the pathophysiology of NASH there is a complex interplay between different organs. Adipose tissue dysfunction is an important driver of disease.
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prof Sven Francque, Belgium discusses the value of the clinical trials results presented in Boston during the Liver meeting 2019.
Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.
June 12 is dedicated to increasing awareness about non-alcoholic steatohepatitis, or NASH, among various populations: the general public, at-risk patients, the medical community, public health authorities, and the media.